Analysis of clinical characteristics of severe mycoplasma pneumoniae pneumonia in children

DOI: 10.12201/bmr.202505.00038

•  

  Abstract: Abstract: To investigate the clinical features and related risk factors of mycoplasma pneumoniae pneumonia (SMPP) in children.Methods The clinical data of 240 children with Mycoplasma pneumoniae pneumonia (MPP) admitted from October 2023 to March 2024 were analyzed, and multivariate logistic regression analysis was used to analyze the risk factors related to the occurrence of SMPP.The ROC curve was plotted to analyze the predictive value of each independent risk factor for SMPP.Results Compared with 119 cases of general Mycoplasma pneumoniae pneumonia (GMPP), the 121 cases of SMPP had longer durations of fever, azithromycin treatment, hospital stay, and glucocorticoid use, higher proportions of glucocorticoid use, unilateral lung lesions, and large patchy lung shadows, higher levels of C-reactive protein (CRP), interleukin (IL)-6, and D-dimer, and lower peripheral blood lymphocyte counts, with statistically significant differences (P<0.05). The results of multivariate analysis showed that heat range, D-dimer and IL-6 were independent risk factors for the development of SMPP. The ROC curve showed that the heat duration ≥ 6.5 days, D-dimer ≥ 0.495 mg/L, IL-6≥11.05 pg/mL, and large patchy opacities in the lungs were of good value in distinguishing children with SMPP and GMPP. Conclusions Prolonged fever, large patchy lung shadows, and elevated levels of D-dimer and IL-6 are helpful for early identification of SMPP.

  Key words: Mycoplasma pneumoniae; Severe; Risk factors; child

  Submit time: 26 May 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• YE Hongzhou, YUAN Chen. Risk factors of severe pneumonia in children with macrolide-resistant Mycoplasma pneumoniae pneumonia and the construction of prediction model. 2024. doi: 10.12201/bmr.202409.00021

  马亚鑫, ZHU Xiaowei, Li Shuqiong, Li Yunxiang, Sun Yonghong. MA Yaxin1, LI Shuqiong1, LI Yunxiang1, SUN Yonghong2▲. 2025. doi: 10.12201/bmr.202504.00073

  GENG Gang, LI Shaojun. Mycoplasma pneumoniae encephalitis in children: a case report and literature review. 2024. doi: 10.12201/bmr.202408.00042

  changyanmei, yulijuan, 孟淑萍. The value of Mycoplasma pneumoniae RNA detection in the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children. 2025. doi: 10.12201/bmr.202506.00025

  ZHANG Xiao-Hua, YANG Yi-Tong. Progress of community-acquired respiratory distress syndrome toxins in Mycoplasma pneumoniae infection in children. 2025. doi: 10.12201/bmr.202506.00057

  Li Feifan, Zhang shuitang. Impact of Mixed Infections and Antibiotic Resistance Genes on Clinical Features in Children with Mycoplasma pneumoniae Pneumonia. 2024. doi: 10.12201/bmr.202412.00025

  周妮, GU Qiang. Risk factors and risk prediction for the course of lobar pneumonia in children. 2025. doi: 10.12201/bmr.202504.00059

  Wu Xiayang. Evaluation of the effectiveness and safety of generic and original azithromycin for the treatment of pediatric mycoplasma pneumonia. 2025. doi: 10.12201/bmr.202501.00071

  gaoweiwei, lijialin, liudaijian, wangyulin. Correlational Analysis of Immune-Inflammatory Markers with the Clinical Outcomes of Severe Pneumonia. 2024. doi: 10.12201/bmr.202409.00062

  wang nan, li lingyan, yang yanhui, gao fangfang, yang mei, qi aixia, chen liping. Analysis of Detection and Epidemiological Characteristics of Respiratory Pathogens in Children in Zibo from 2020 to 2022. 2025. doi: 10.12201/bmr.202504.00019

• ID	Submit time	Number	Download
  1	2025-03-22	bmr.202505.00038V1	Download

• Public  Anonymous  To author only Submit Comments